推荐理由:Incyte 通过收购 Star biotech 旗下 Vega Therapeutics 切入出血性疾病领域,可观察其血液学管线的外延方向。
#License/BD
#License/BD
今日 1 条
Incyte@Incyte精选AI 评分5252
Fierce PharmaAI 评分3636 Fierce Pharma Asia—中国生物科技更趋鹰派;辉瑞与信达生物达成100亿美元交易;安斯泰来路线图
辉瑞与信达生物达成100亿美元交易。Fierce Pharma Asia报道还涉及中国生物科技行业更趋鹰派的动向,以及安斯泰来的路线图。
Dr. Reddy’s Laboratories Ltd@drreddysAI 评分22
Incyte@IncyteAI 评分2222Incyte 与 @genesismolai 正在扩大我们的合作,旨在加速潜在新药的发现。了解更多。https://bit.ly/4uiY5sl

Incyte@IncyteAI 评分3535引用Sam Rodriques@SGRodriquesWe live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. @Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.
Incyte@IncyteAI 评分2222我们很高兴宣布与@EdisonSci达成战略合作,将在Incyte的发现与开发全生命周期中应用Kosmos AI平台。了解更多。https://bit.ly/4dvd37o

Regeneron@RegeneronAI 评分2222今天我们宣布与Parabilis Medicines达成合作,将再生元行业领先的抗体能力与Parabilis新型Helicon™肽平台相结合。 了解更多:https://bit.ly/4wyoeEW
Regeneron@RegeneronAI 评分2222
Boehringer Ingelheim@BoehringerAI 评分4040
Boehringer Ingelheim@BoehringerAI 评分4040
Boehringer Ingelheim@BoehringerAI 评分2525
Boehringer Ingelheim@BoehringerAI 评分2222
Boehringer Ingelheim@BoehringerAI 评分1818
Boehringer Ingelheim@BoehringerAI 评分1818
Sinovac Biotech@SinovacAI 评分1818科兴副总裁会见巴西领导人,推动当地疫苗生产——推进人用狂犬病疫苗和水痘疫苗的可及性,加强#巴西-#中国卫生合作。 我们正共同迈向疫苗可及与卫生独立。#vaccine #GlobalHealth
Boehringer Ingelheim@BoehringerAI 评分3838
Boehringer Ingelheim@BoehringerAI 评分4242